Menlo Therapeutics Inc., a late-stage biopharma company that specializes in developing treatments for itchy skin disorders, has filed for an initial public offering to raise at least $85 million. The company said it is applying to list on Nasdaq under the ticker symbol “MNLO”. Jefferies, Piper Jaffray, Guggenheim Securities are joint bookrunners on the deal with JMP Securities acting as lead manager.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News